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Summary
Background—Malawi, which has about 80 000 deaths from AIDS every year, made free
antiretroviral therapy available to more than 80 000 patients between 2004 and 2006. We aimed to
investigate mortality in a population before and after the introduction of free antiretroviral therapy,
and therefore to assess the effects of such programmes on survival at the population level.
Methods—We used a demographic surveillance system to measure mortality in a population of
32 000 in northern Malawi, from August, 2002, when free antiretroviral therapy was not available
in the study district, until February, 2006, 8 months after a clinic opened. Causes of death were
established through verbal autopsies (retrospective interviews). Patients who registered for
antiretroviral therapy at the clinic were identified and linked to the population under surveillance.
Trends in mortality were analysed by age, sex, cause of death, and zone of residence.
Findings—Before antiretroviral therapy became available in June, 2005, mortality in adults (aged
15–59 years) was 9·8 deaths for 1000 person-years of observation (95% CI 8·9–10·9). The probability
of dying between the ages of 15 and 60 years was 43% (39–49) for men and 43% (38–47) for women;
229 of 352 deaths (65·1%) were attributed to AIDS. 8 months after the clinic that provided
antiretroviral therapy opened, 107 adults from the study population had accessed treatment, out of
an estimated 334 in need of treatment. Overall mortality in adults had decreased by 10% from 10·2
to 8·7 deaths for 1000 person-years of observation (adjusted rate ratio 0·90, 95% CI 0·70–1·14).
Mortality was reduced by 35% (adjusted rate ratio 0·65, 0·46–0·92) in adults near the main road,
where mortality before antiretroviral therapy was highest (from 13·2 to 8·5 deaths per 1000 person-
years of observation before and after antiretroviral therapy). Mortality in adults aged 60 years or
older did not change.
Interpretation—Our findings of a reduction in mortality in adults aged between 15 and 59 years,
with no change in those older than 60 years, suggests that deaths from AIDS were averted by the
rapid scale-up of free antiretroviral therapy in rural Malawi, which led to a decline in adult mortality
that was detectable at the population level.
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Introduction
The combination of high rates of HIV infection and the substantial decrease in life expectancy
for people with untreated HIV/AIDS has changed mortality rates at the population level in
many African countries. However, although this can be demonstrated in models, empirical
evidence for this effect on populations has been limited to a few community-based
demographic surveillance studies since most African countries do not record vital registration
data. Studies of changes in mortality rates associated with HIV/AIDS need information about
the HIV status of individuals or about the causes of death, which can be ascertained by so-
called verbal autopsies (retrospective interviews) or, more indirectly, by assessment of age-
specific and sex-specific mortality.
Antiretroviral therapy greatly improves survival in HIV patients. Cohort studies have shown
sustained reductions in mortality rates in treated patients, in both developing and developed
countries. The scale-up of programmes for antiretroviral therapy is proceeding fast, to the
extent that the survival benefits might now be detectable at the population level.
In Malawi, adult HIV prevalence has stabilised at about 14% since the late 1990s. Antiretroviral
therapy was first available in the central and southern regions, from three sites (two free and
one with subsidised costs) that treated only 1500 people by 2002. With support from the Global
Fund for AIDS, Tuberculosis and Malaria, a national programme providing free access to
antiretroviral therapy began in Malawi in 2004, and by the end of December, 2006, 81 821
patients had registered for this treatment.
As part of the Karonga Prevention Study in northern Malawi, we investigated the effect of the
introduction of antiretroviral therapy on HIV-related mortality within a population under a
demographic surveillance system based on continuous registration.
Methods
In 2002, we set up a demographic surveillance system based on continuous registration in a
population of 32 000 in Karonga district. The methods have been described in detail
elsewhere. An initial house-to-house census recorded personal identifiers and
sociodemographic data for all individuals, and economic data and physical locations for all
households. Continuous demographic surveillance was launched successively in 230
geographically defined clusters, each with 15–60 households, immediately after completion
of the census in the respective cluster. Within each cluster, one village informant was trained
to record and report births, deaths, and migrations. Births and deaths were followed up every
month by investigators, and migrations were checked every year. A new census of the total
population, which was initiated 2 years after the start to assess the accuracy and completeness
of continuous registration, showed that the routine system had registered 516 (99%) of 521
deaths, 1540 (97%) of 1588 births, and 12 115 (92%) of 13 168 migrations.
The national programme of free (at the point of delivery) antiretroviral therapy started in June,
2004. At that time, the nearest clinic was located about 200 km from the study area. The first
clinic that provided antiretroviral therapy in Karonga district opened in June, 2005, in Karonga
town, which is 80 km from the study area. According to national guidelines, patients who had
HIV/AIDS in WHO clinical stage 3 or 4 or in stage 2 with a CD4 cell count of less than 250
cells per mm3 were started on a standard antiretroviral therapy regimen (of stavudine,
lamivudine, and nevirapine) at the Karonga clinic.
Malawi's north–south highway bisects the study area, and is the only tarmac road with public
transport that links the study area to the town of Karonga. A short tarmac slip-road inside the
study area leads to a small port and truck stop on the lake. Houses are typically scattered, in
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the north of Malawi, without obvious village boundaries, but the study area included a zone of
higher density settlement, with local bars and trading centres located along the highway and
by the truck stop at the lake. Previous fieldwork had shown that the population in this zone
was more economically active and mobile than the rest of the population, and that HIV
prevalence was much higher than in the more remote areas. A higher density zone around the
tarmac roads was defined to stratify the population geographically. We used ArcView 3.1 for
spatial analysis to determine the distance from the midpoints of clusters to the nearest road.
Figure 1 shows a map of the relative household density in the study area and the delineation
of the 1 km zone around the tarmac roads. Clusters with midpoints within 1 km of the roads
covered 21% of the study area, and 41 139 person-years (51% of the entire study population)
were observed within this zone.
Each death was assigned to a cluster on the basis of the household membership of the deceased
at the time of death. This definition excluded short-term moves (eg, for nursing care) that might
have occurred before the death. Health assistants with additional training did verbal autopsies
for all deaths within the continuous registration area. They used a semistructured questionnaire
that was based on the INDEPTH standardised verbal autopsies questionnaire, an adaptation of
the standard WHO questionnaire. Questionnaire data for each person were supplemented by a
review of patient-held health records, hospital case notes, and any previous HIV test results
recorded by other related studies in the area. Since 2005, interviewers asked specifically
whether the deceased had been on antiretroviral therapy. Three medically or paramedically
qualified individuals (medical doctors or clinical officers) independently reviewed each
questionnaire to assign the most likely underlying cause of death. Direct causes of death (eg,
cryptococcal meningitis in AIDS cases) were not coded. For deaths attributable to tuberculosis,
HIV/AIDS was defined as the underlying cause if symptoms of immunosuppression preceded
the onset of cough or other symptoms of tuberculosis, or if the individual was known to be
HIV positive. If the temporal sequence between signs of immunosuppression and tuberculosis
was not clear, the cause of death was classified as “tuberculosis or AIDS”. Discrepantly coded
cases were discussed and resolved if possible, or coded as “non-specifiable” if consensus could
not be reached.
All patients who attended the Karonga clinic for antiretroviral therapy were also invited to
participate in a separate operational study that consisted of active home follow-ups of non-
attenders. More than 95% of patients consented to participate in that study, and their identity
details were stored in a secured area of the central project database. Ethical approval for these
studies was obtained from the National Health Sciences Research Committee of Malawi and
the ethics committee of the London School of Hygiene and Tropical Medicine.
Statistical analysis
We assessed overall and cause-specific mortality rates. To define the person-time denominator
in the population, we observed every individual from the time they were first seen in the
baseline census, from birth, or from the date of migration into the area after the baseline census,
until the day of their death (if they were still a member of a household in the area at the time
of death) or until migration out of the area. Multiple episodes of observation (and gaps) were
allowed if individuals moved out of the surveillance area and later returned.
To allow comparison with other studies, crude and age-standardised death rates (for the whole
population) and the age-standardised death rate for adults of 15 years and older are also
presented, with direct standardisation to the INDEPTH standard population for sub-Saharan
Africa. For the analysis of all-cause mortality, the failure event was death. To estimate AIDS-
specific mortality, the failure event was death from AIDS or “tuberculosis or AIDS”; deaths
from all other known and unknown causes were censored. To estimate mortality from all other
causes except AIDS, we censored deaths from AIDS and deaths from tuberculosis or AIDS.
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Because of the staggered start of the baseline census for continuous registration, geographical
areas contributed different amounts of observation time in different calendar periods. We
therefore calculated the probability of dying between certain ages before antiretroviral therapy
was available with a Poisson regression model, weighted by the relative population size in the
different enumeration areas. The lifetime risk of dying of HIV/AIDS was calculated from the
Kaplan-Meier failure function as the cumulative probability of dying from AIDS when the
curve reached its plateau (at 70 years of age).
To assess the effect of antiretroviral therapy, mortality rates were initially compared between
three periods: before the start of the national roll-out, when antiretroviral therapy became
available in the northern region, and when antiretroviral therapy became available in Karonga
Town. Since mortality rates had not changed before the opening of the Karonga clinic (data
not shown), we compared mortality rates in the first two periods combined, with those from
the last period. To allow for the staggered start of the baseline census, we adjusted mortality
rate ratios for enumeration area. We also adjusted them for age and sex to account for potential
changes in age distribution and sex ratio over time. The Poisson regression model was stratified
according to age (15–29, 30–44, 45–59, and 60 years and older) and according to the distance
of each area of residence to the nearest tarmac road (whether 1 km or less, or more than 1 km).
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data
interpretation, or writing of the report. The corresponding author had full access to all the data
in the study and had final responsibility for the decision to submit for publication.
Results
Between August, 2002, and the end of February, 2006, we recorded 916 deaths in 39 321
individuals during 81 278 person-years of observation, which equates to a crude death rate of
11 per 1000 per year (95% CI 10·6–12·0) and an age-standardised death rate of 12 per 1000
person-years of observation. Of these deaths, 574 were in adults older than 14 years (for whom
we recorded 42 657 person-years of observation), and 373 deaths were in 18 927 adults aged
15–59 years (with 38 015 person-years of observation). Therefore, the adult mortality rate was
9·8 per 1000 person-years of observation (95% CI 8·9–10·9), with 9·6 (8·3–11·1) in men and
10·0 (8·6–11·5) in women.
269 (46·9%) of the 574 deaths in adults older than 14 years occurred at health facilities, 262
(45·6%) at home, 30 (5·2%) outdoors, and 13 (2·3%) at traditional healer camps. Table 1 shows
the probable causes for these 574 deaths. Verbal autopsies were available for 570 (99·3%), and
a probable cause was established for 509 deaths (227 [88%] of men and 282 [89%] of women).
More female than male deaths were attributed to AIDS: 145 (51%) of 282 women died of
AIDS, compared with 98 (43%) of 227 men (p=0·065).
Of the 373 deaths in adults aged 15–59 years, verbal autopsies were available for 372 (99·4%).
In this age-group, probable causes were established for 352 deaths (159 [91·4%] of deaths in
men and 192 [96·5%] in women). 229 (65·1%) of these 352 deaths were attributed to AIDS.
139 (72·0%) women and 90 (56·6%) men died of AIDS—ie, 60·7% of all AIDS deaths were
in women.
Mortality rates from all causes by sex and age in the period before antiretroviral therapy was
introduced in June 2005 are shown in Figure 2. Death rates initially peaked between the ages
of 40 and 44 years for both men and women, and then rose again at later ages. Death rates
increased at an earlier age in women than in men; and were 3·4 times higher (95% CI 1·3–8·9)
at age 20–24 years (adjusted for area). This differential was lost by the ages of 30–34 years,
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and at older ages rates of death in women were slightly lower than in men. Figure 2 also shows
age-specific and sex-specific mortality from AIDS and from all other causes combined for the
same period; the high mortality in young women and the peak between the ages of 40 and 44
years is clearly attributable to AIDS. Overall adult mortality from all causes was almost
identical in women and men (rate ratio [RR] adjusted for age and area 0·97, 95% CI 0·81–
1·17), but AIDS-specific mortality was higher in women (RR adjusted for age and area 1·36,
1·01–1·82). The overall age-standardised AIDS mortality rate in adults older than 14 years was
6·3 deaths per 1000 person-years of observation, with 4·9 in men and 6·5 in women.
Figure 3 and table 2 show survival probability by age and adult mortality risks in the period
before antiretroviral therapy. Before the opening of the Karonga clinic, the probability of dying
from any cause between the exact ages of 15 and 60 years (45q15, adjusted for area) was 43%
(95% CI 39–49) for men and 43% (38–47) for women. Of the 289 deaths in adults aged 15–
59 years in this period, 181 (63%) were attributed to AIDS. The probability of dying of any
cause other than AIDS between ages 15 and 60 years (45q15, adjusted for area) was 19% (95%
CI 15–25) for men and 15% (12–20) for women. Two other measures for the probability of
dying are shown in table 2 to allow comparison with other studies. Assuming unchanged HIV-
incidence and mortality, a child born into the surveillance population before the introduction
of antiretroviral therapy would have had a 37% lifetime risk of dying from AIDS (35% for
boys and 38% for girls).
Overall mortality rates before and after opening of the antiretroviral therapy clinic in Karonga
district are shown in table 3. After the opening of the clinic, all-cause mortality in adults aged
15–59 years decreased by 10% (the rate ratio [RR] adjusted for age, sex, and area was 0·90,
95% CI 0·70–1·15), which is equivalent to nine deaths averted in the 8-month observation
period after introduction of antiretroviral therapy. All-cause mortality in individuals aged 60
years and older did not change. AIDS mortality decreased by 19% in the 15–59-year age-group
(adjusted RR 0·81, 0·58–1·12), with no change in mortality from causes other than AIDS.
Trends in adult mortality differed in the two zones that were defined according to distance from
the tarmac road (p=0·003, test for interaction in adults aged 15–59 years). Mortality in adults
aged 15–59 years before the introduction of antiretroviral therapy was much higher in the 1
km zone close to the tarmac roads than in the rest of the study area (rate ratio [RR] 1·91, 95%
CI 1·49–2·48). Table 3 shows that the mortality rate was reduced by 35% in adults aged 15–
59 years who lived within 1 km of the tarmac roads (RR adjusted for age and area 0·65, 0·46–
0·92) after the opening of the antiretroviral therapy clinic. Reductions were seen in each of the
age-groups, 15–29, 30–44, and 45–59 years. In the zone further away from the road, mortality
increased slightly in those aged 15–59 years. Mortality rates in adults aged 60 years or older
did not change in either zone (area-adjusted RR: 1 km-zone 0·99, remote zone 1·03).
In the zone within 1 km of the tarmac roads, AIDS mortality in adults aged 15–59 years was
reduced by 33% after the opening of the Karonga antiretroviral therapy clinic (rate ratio [RR],
adjusted for age, sex, and area 0·67, 95% CI 0·44–1·03) and little change was seen in the more
remote zone (RR, adjusted for age, sex, and area 1·07, 0·64–1·79). Deaths that were classified
as not related to AIDS also decreased close to the road (RR adjusted for age, sex, and area 0·57,
0·30–1·10), but increased further from the road (RR adjusted for age, sex, and area 2·36, 1·32–
4·20). 11 men and 12 women died of causes other than AIDS in the remote zone after the
introduction of antiretroviral therapy (five from gastrointestinal causes, four cardiovascular,
four cancer, three meningitis, three accidents, two from tuberculosis, and one maternal death).
Of adults aged 15–59 years who died, three had moved from the near zone to the more remote
zone and two in the other direction before the introduction of antiretroviral therapy. After the
clinic opened, three moved from the near to the more remote zone.
Jahn et al. Page 5
Published as: Lancet. 2008 May 10; 371(9624): 1603–1611.
Sponsored D
ocum
ent 
 Sponsored D
ocum
ent 
 Sponsored D
ocum
ent
By the end of the observation period, in February, 2006, 99 adults from the study population
had accessed antiretroviral therapy at the Karonga clinic and 12 of these (seven women and
five men) died during the observation period. The verbal autopsies revealed that an additional
eight adults (five women and three men) had received antiretroviral therapy before their death,
but had not been identified at the Karonga clinic and therefore apparently received treatment
from another source, some probably before the opening of the Karonga clinic in June, 2005.
Overall 12 women and eight men who had antiretroviral therapy died during the observation
period (accounting for 8% of AIDS deaths).
Of all 107 adults (74 women and 33 men) known to have accessed antiretroviral therapy, 78
(73%) lived within 1 km of the tarmac roads. The rate of access per person-years of observation
in people near the road was 2·6 times that in the more distant zone (p<0·0001).
Discussion
Malawi's population of 12·5 million has been severely affected by a generalised HIV epidemic
since the early 1990s. In the absence of a vital registration system or reliable mortality statistics
from the health services, AIDS mortality has been estimated with mathematical models (EPP
and Spectrum) based on HIV-prevalence data from antenatal sentinel surveillance. More than
half of all adults who died in the study population did so outside of health facilities, which is
typical of other rural African settings, and explains why facility-based analyses of mortality
would not be representative in these settings.
Analysis of age-specific mortality and survival in the population showed that premature deaths
of adults aged 15–59 years were associated with the effect of the HIV epidemic. Before the
antiretroviral therapy clinic opened, the probablility of dying between the ages of 15 and 60
years for men was 43%, and 63% of deaths in this age-group were attributed to AIDS. This is
in line with other studies when the prevalence of HIV is taken into account. Adult HIV-
prevalence in the study population in 2005 was about 11·4%, which was lower than national
estimates of 14·4% in 2003 from antenatal surveillance and 12% in 2004 from a general
population sample. Based on the assumed national prevalence of 14·4%, WHO models predict
a mortality risk in men aged between 15 and 60 years of 66% for Malawi. In the era before the
HIV epidemic, male adult mortality in sub-Saharan Africa was assumed to range between 20%
and 50%, and values below 40% have been projected for countries with low HIV prevalence
in West and Central Africa. A review of WHO and UNAIDS projections showed estimates of
greater than 60% for adult mortality in nine of 12 countries in sub-Saharan Africa that had HIV
prevalences of more than 10%. Our result for the mortality rate from AIDS in adults,
standardised for age (6·3 deaths per 1000 person-years of observation), was much higher than
empirical estimates, based on verbal autopsies from three other demographic surveillance sites.
In Tanzania, which had a lower prevalence of HIV, the rates were 1·3 deaths per 1000 person-
years of observation in Rufiji and 1·8 in Ifakara. In Manhiça, Mozambique, the rate was 2·4
deaths per 1000 person-years of observation. In KwaZulu Natal, South Africa, where the HIV
prevalence was estimated at 21·5% in 2003–04, the rate was 11·4 per 1000 person-years of
observation.
Our results show not only the effect of HIV on mortality at the population level, but also the
beginning of a reversal of this effect by antiretroviral therapy. After the opening of the first
clinic in the district, mortality rates fell by 10% in 15–59-year-olds. In the area close to the
roads, where baseline mortality rates were much higher, associated with higher HIV
prevalences, all-cause mortality fell by 35% (rate ratio 0·65, 0·46–0·92).
Detection of effects at the population level such a short time after the introduction of
antiretroviral therapy in the district might seem surprising, but could be expected from the high
proportion of deaths attributable to HIV before the clinic opened (65%), the high HIV
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prevalence (11% overall and higher near the road), good uptake of antiretroviral therapy, and
the ability of such treatment to prevent deaths which would otherwise be imminent.
Using mathematical models fitted to repeated surveys of the seroprevalence of HIV, we have
previously estimated that about 2% of adults in Karonga district needed antiretroviral therapy
in 2005 (ie, would have died within 2 years). If we assume that the demographic surveillance
area is typical of the district as a whole, 334 of the 16 720 adults aged 15 years and older in
the surveillance population needed treatment. By the end of February, 2006, 8 months after
the opening of the Karonga clinic, 107 adults in the study population—almost a third of those
who were in need—had accessed antiretroviral therapy. 60·1% of all patients at the clinic were
women. That a similar proportion (60·7%) of AIDS deaths in our study population were in
women suggests that access to treatment was balanced between the sexes. A community-based
study from the era before antiretroviral therapy in Malawi reported high rates of mortality in
HIV patients eligible for antiretroviral therapy (62 and 88 deaths per 100 person-years of
observation for patients in clinical stages 3 and 4, respectively). Data from the programme in
Malawi have shown that 81% of patients survived after 6 months of antiretroviral therapy, and
74% after 12 months. Data from the Ministry of Health's routine monitoring of the Karonga
clinic show that of 1091 patients who registered from June, 2005, to September, 2006, 452
(41·4%) were in clinical stage 3 and 615 (56·4%) were in stage 4. The mortality risk was 25·0%
within the first 6 months after initiation of antiretroviral therapy and declined rapidly with time
on antiretroviral therapy: only 41 (19·4%) of the 211 deaths occurred after the third month
(Prof AD Harries, personal communication). Of the 99 patients of the Karonga clinic who were
in the study population, 66 (66·7%) had initiated antiretroviral therapy before December, 2005
—ie, more than 3 months before the end of the observation period. With respect to the
substantial effect that antiretroviral therapy has on survival and the large number of adults in
the surveillance population who had accessed antiretroviral therapy, our findings about
reductions in mortality in the study population can plausibly be attributed to antiretroviral
therapy.
This high uptake of antiretroviral therapy in the study area is encouraging, especially since,
although treatment was free, visits to the clinic cost about US$3 by public transport, whereas
the average monthly household income in this population was US$23 in 2004.
Our finding that deaths not related to AIDS decreased in the zone near the main roads but not
in the more remote zone might be attributable to some misclassification in causes of death.
Some of the 23 deaths attributed to other causes (eg, the three deaths from meningitis and two
from tuberculosis) could in fact have been due to HIV. Previous studies have shown that
analyses of verbal autopsies alone, without knowledge of HIV status, can underestimate deaths
caused by AIDS. Therefore, assessments of mortality due to AIDS by use of verbal autopsies
alone might not be valid. Systematic assessments of the ascertainment of AIDS deaths by verbal
autopsies have shown that their sensitivity ranges from 76% to 92%, and that they have a
specificity of 66% compared with diagnoses based on HIV serostatus. HIV status was only
known for a few of those who died. The proportion of individuals with known HIV status rose
later in the study. 19% of those who died in the near zone before treatment was available were
known to be HIV positive, compared with 30% of those who died after the clinic was set up;
further from the road the proportions were 13% and 16%, respectively. The increase in the
availability of positive results after the clinic opened could have increased the proportion of
deaths attributed to AIDS in the zone close to the road, and contributes to the apparent decline
in other deaths in this area.
Since few people moved between the two zones, the observed changes in mortality cannot be
explained by migration. The rate of deaths from causes other than AIDS was relatively low in
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the more remote zone before the clinic opened, which could have contributed to the apparent
rise in such deaths in this area.
The fact that mortality fell in the age-group known to be affected most by AIDS mortality (15–
59 years), but remained unchanged in older adults, adds credence to the interpretation that the
observed trend was due to a reduction in AIDS deaths. Other external changes (eg, in the food
supply) would be expected to increase mortality more in older than in younger adults.
The surveillance area contained about 12% of the adult population of the district but 16% of
those who attended the Karonga clinic. This suggests that access to antiretroviral treatment in
the study area was slightly higher than average in the population. Implementation of
antiretroviral therapy across Malawi continues to accelerate, including a new public clinic in
the surveillance area since September, 2006. With continuing decentralisation and increased
access, population mortality rates should continue to fall.
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Figure 1.
Map of the study area showing the distribution of households
Grid of 250 m × 250 m relative to the mean household density in the whole study area (45
households per km2). The zone of clusters with midpoints within 1 km of the nearest road is
marked.
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Figure 2.
Mortality rates by sex and age-group before availability of antiretroviral therapy
Data are from August, 2002 to June, 2005, with 438 deaths in 31 665 person-years of
observation.
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Figure 3.
Kaplan–Meier survival function for the entire study population before introduction of
antiretroviral therapy
Data are from August, 2002, to June, 2005, with 438 deaths in 31 665 person-years of
observation.
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Table 1
Probable causes of death in 574 adults aged older than 14 years
Men Women
15–44 years 45–59 years ≥60 years Total 15–44 years 45–59 years ≥60 years Total
Communicable diseases 83 (68·6%) 30 (56·6%) 22 (26·2%) 135 (52·3%) 115 (78·8%) 37 (69·8%) 29 (24·8%) 181 (57·3%)
HIV/AIDS 61 (50·4%) 22 (41·5%) 8 (9·5%) 91 (35·3%) 99 (67·8%) 32 (60·4%) 5 (4·3%) 136 (43·0%)
Tuberculosis or HIV/AIDS 6 (5·0%) 1 (1·9%) 0 7 (2·7%) 7 (4·8%) 1 (1·9%) 1 (0·9%) 9 (2·8%)
Tuberculosis 5 (4·1%) 0 1 (1·2%) 6 (2·3%) 0 2 (3·8%) 4 (3·4%) 6 (1·9%)
Pneumonia 2 (1·7%) 3 (5·7%) 6 (7·1%) 11 (4·3%) 2 (1·4%) 1 (1·9%) 8 (6·8%) 11 (3·5%)
Malaria 0 0 1 (1·2%) 1 (0·4%) 0 0 0 0
Acute febrile disease, non-
specifiable
3 (2·5%) 1 (1·9%) 0 4 (1·6%) 1 (0·7%) 0 7 (6·0%) 8 (2·5%)
Other communicable disease 6 (5·0%) 3 (5·7%) 6 (7·1%) 15 (5·8%) 6 (4·1%) 1 (1·9%) 4 (3·4%) 11 (3·5%)
Non-communicable diseases 15 (12·4%) 16 (30·2%) 44 (52·4%) 75 (29·1%) 23 (15·8%) 14 (26·4%) 58 (49·6%) 95 (30·1%)
Cardiovascular 0 6 (11·3%) 22 (26·2%) 28 (10·9%) 2 (1·4%) 8 (15·1%) 33 (28·2%) 43 (13·6%)
Gastrointestinal 7 (5·8%) 2 (3·8%) 6 (7·1%) 15 (5·8%) 5 (3·4%) 3 (5·7%) 7 (6·0%) 15 (4·7%)
Direct obstetric 0 0 0 0 11 (7·5%) 0 0 11 (3·5%)
Cancer 2 (1·7%) 2 (3·8%) 3 (3·6%) 7 (2·7%) 3 (2·1%) 2 (3·8%) 8 (6·8%) 13 (4·1%)
Endocrine 2 (1·7%) 1 (1·9%) 3 (3·6%) 6 (2·3%) 0 0 3 (2·6%) 3 (0·9%)
Respiratory 0 1 (1·9%) 0 1 (0·4%) 0 0 1 (0·9%) 1 (0·3%)
Other non-
communicable disease
4 (3·3%) 4 (7·5%) 10 (11·9%) 18 (7·0%) 2 (1·4%) 1 (1·9%) 6 (5·1%) 9 (2·8%)
External causes 11 (9·1%) 4 (7·5%) 2 (2·4%) 17 (6·6%) 2 (1·4%) 1 (1·9%) 3 (2·6%) 6 (1·9%)
Accidental 8 (6·6%) 4 (7·5%) 1 (1·2%) 13 (5·0%) 2 (1·4%) 0 2 (1·7%) 4 (1·3%)
Suicide 1 (0·8%) 0 1 (1·2%) 2 (0·8%) 0 0 1 (0·9%) 1 (0·3%)
Homicide 0 0 0 0 0 1 (1·9%) 0 1 (0·3%)
Unknown intent 2 (1·7%) 0 0 2 (0·8%) 0 0 0 0
Cause of death unknown 12 (9·9%) 3 (5·7%) 16 (19·0%) 31 (12·0%) 6 (4·1%) 1 (1·9%) 27 (23·1%) 34 (10·8%)
Total 121 (100·0%) 53 (100·0%) 84 (100·0%) 258 (100·0%) 146 (100·0%) 53 (100·0%) 117 (100·0%) 316 (100·0%)
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Table 2
Probability of dying between the ages of 15 and 60, 20 and 50, and 30 and 65 years in the surveillance population
before opening of the antiretroviral therapy clinic in June, 2005, adjusted for area
All-cause mortality Mortality from all causes except AIDS
Deaths Person-years of observation Probability Deaths Person-years of observation Probability
All Men Women All Men Women All Men Women All Men Women All Men Women All Men Women
Ages 15–
60 years
289 131 158 28 
244
13 
459
14 786 43% 43% 43% 89 51 38 28 
244
13 
459
14 786 17% 19% 15%
Ages 20–
50 years
229 103 126 19 
696
9372 10 323 30% 31% 30% 57 33 24 19 
696
9 
372
10 323 10% 12% 9%
Ages 30–
65 years
244 124 120 12 
685
5772 6913 45% 45% 44% 76 46 30 12 
685
5 
772
6913 20% 22% 18%
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Table 3
Trends in adult mortality before and after opening of the antiretroviral clinic in Karonga district
All causes Adults 15–59 years
15–
29 years
30–
44 years
45–
59 years
≥ 60 years 15–
59 years
All ≥15 years AIDS death Non-
AIDS death
Unknown
cause of
death
Entire study population
Before antiretroviral therapy
Deaths 59 148 82 149 289 438 181 89 19
Person-
years of observation
16 347 7866 4031 3421 28 244 31 665 28 244 28 244 28 244
Deaths per 1000 person-
years of observation
3·6 18·8 20·3 43·6 10·2 13·8 6·4 3·2 0·7
After antiretroviral therapy
Deaths 16 44 25 51 85 136 48 34 3
Person-
years of observation
5587 2840 1344 1220 9771 10 991 9771 9771 9771
Deaths per 1000 person-
years of observation
2·9 15·5 18·6 41·8 8·7 12·4 4·9 3·5 0·3
Adjusted rate ratio 0·83 (0·47–
1·47)*
0·86 (0·61–
1·21)*
0·98 (0·62–
1·56)*
1·00 (0·73–
1·38)*
0·90 (0·70–
1·15)†
0·94 (0·77–
1·14)†
0·81 (0·58–
1·12)†
1·16 (0·77–
1·75)†
0·52 (0·16–
1·70)†
Area closer than 1 km to the road
Before antiretroviral therapy
Deaths 35 105 56 85 196 281 124 61 11
Person-
years of observation
8695 4119 1985 1814 14 799 16 613 14 799 14 799 14 799
Deaths per 1000 person-
years of observation
4·0 25·5 28·2 46·9 13·2 16·9 8·4 4·1 0·7
After antiretroviral therapy
Deaths 9 20 11 27 40 67 26 11 3
Person-
years of observation
2 713 1368 638 582 4720 5302 4720 4720 4720
Deaths per 1000 person-
years of observation
3·3 14·6 17·2 46·4 8·5 12·6 5·5 2·3 0·6
Adjusted rate ratio 0·84 (0·40–
1·80)*
0·58 (0·36–
0·94)*
0·64 (0·33–
1·24)*
0·99 (0·64–
1·52)*
0·65 (0·46–
0·92)†
0·76 (0·57–
0·99)†
0·67 (0·44–
1·03)†
0·57 (0·30–
1·10)†
0·88 (0·25–
3·04)†
Area further than 1 km from the road
Before antiretroviral therapy
Deaths 24 43 26 64 93 157 57 28 8
Person-
years of observation
7651 3747 2047 1607 13 445 15 052 13 445 13 445 13 445
Deaths per 1000 person-
years of observation
3·1 11·5 12·7 39·8 6·9 10·4 4·2 2·1 0·6
After antiretroviral therapy
Deaths 7 24 14 24 45 69 22 23 0
Person-
years of observation
2873 1472 706 638 5052 5689 5052 5052 5052
Deaths per 1000 person-
years of observation
2·4 16·3 19·8 37·6 8·9 12·1 4·4 4·6 0
Adjusted rate ratio 0·82 (0·35–
1·94)*
1·48 (0·88–
2·49)*
1·72 (0·87–
3·31)*
1·03 (0·64–
1·66)*
1·37 (0·94–
1·98)†
1·24 (0·92–
1·65)†
1·07 (0·64–
1·79)†
2·36 (1·32–
4·20)†
..
*
Rate ratio, adjusted for area and sex, with 95% CI.
†
Rate ratio, adjusted for area, sex, and age, with 95% CI.
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